October 15, 2019 08:52 AM EDTUpdated 11:44 AM
R&D

That big neu­ro­sciences R&D group Eli Lil­ly built is be­ing dis­man­tled, with lay­offs and parts shipped home

John Carroll

Editor & Founder

Sev­en years af­ter Eli Lil­ly bulked up its neu­ro­sciences re­search group in Sur­rey and her­ald­ed the move as an in­di­ca­tion of its com­mit­ment to the field, the phar­ma gi­ant is shut­ting down and lock­ing up labs.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Cash, chips and tal­ent: In­side Nvidi­a's plan to dom­i­nate biotech's AI rev­o­lu­tion

A ma­jor­i­ty of phar­ma and biotech com­pa­nies pro­hib­it Chat­G­PT use, sur­vey finds

Sen­ate bill tar­get­ing WuXi won't af­fect fed­er­al spend­ing, CBO says

GSK un­veils long-term Shin­grix da­ta as shin­gles com­pe­ti­tion heats up

Ver­tex, Alpine’s IgAN drug has Hu­mi­ra-like po­ten­tial. But not all in­di­ca­tions are cre­at­ed equal

Rare neu­ro dis­or­der of­fers new area for com­pe­ti­tion, an­a­lysts say: #AAN24

A service from the Financial Times